Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

trial (4Q08).

-- ENMD-2076 is an oral selective kinase inhibitor with a unique kinase

profile, including antiproliferative activity and inhibition of

angiogenesis. ENMD-2076 has demonstrated potent antitumor activity as a

single agent in multiple preclinical models, including tumor regression

in breast, colon, and leukemia models without cardiovascular effects.

ENMD-2076 is a unique-in-class compound that inhibits both Aurora A and

growth factor receptors critical to angiogenesis.

-- EntreMed's IND has been accepted by the FDA and a Phase 1 study in

solid tumors is expected to enroll patients in early 2Q08. EntreMed has

been selected for an oral presentation on ENMD-2076 during the American

Association for Cancer Research's "Drugs on the Horizon" symposium to

be held during the AACR annual meeting in April. ENMD-2076 milestones

for 2008 include initiating a Phase 1 trial in solid tumors (1Q08);

initiating a Phase 1 trial in hematological tumors (3Q08/4Q08); and

entering into a development alliance (2H08/1H09).

-- EntreMed plans to discontinue development of 2ME2 (Panzem(R) NCD) for

oncology. Modest antitumor activity has been shown across most of the

clinical studies, yet there is not a clear development path that would

narrow the indications for larger randomized studies. Additional trial

costs, the high doses required for use in oncology, and

manufacturing/process development expenditures would together require

the commitment of a disproportionate amount of resources and limit

clinical development efforts on the remainder of the pipeline. Patients

still on clinical oncology trials, however, will continue to receive

Panzem(R) NCD.

-- EntreMed plans to move 2ME2 forward in rheumatoid arthritis based on

the knowledge gained from the oncolo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ... With a focus on evidence-based research and clinical application, the event gathered industry ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) ... humor and excellent customer service. Images such as the Fonz in a lab coat ... some flavor to the humdrum spectroscopy field. , FireflySci is proud to be ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... ... to provide online tutorial suite, Quick Reference Cards, and other training and outreach programs. ... Seattle, WA (PRWEB) April 13, ... has partnered with OpenHelixTM to provide comprehensive training and outreach programs for its ...
... Researchers at Uppsala University have developed a new method ... Hopes are strong that the method represents an important ... new diagnostic tests. The new method, which ... should enable studies of the effects of genetic variation ...
... ... Deliver Results Faster with New User Interface and Improved Support for Complex Experiments. ... (PRWEB) April 12, ... life science research, today announced Genedata Screener® 8. Developed over the past year to ...
Cached Biology Technology:RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 2RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 3Mutations directly identifiable in active genes 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 3Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 4
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... of Marine Geology and Geophysics at the University of Miami ... off the fall semester with the inauguration of sophisticated equipment ... manner. Stable isotopes are used by biogeochemists to help ... using small organisms found in sediment cores. ...
... October issue of Infection Control and Hospital Epidemiology, ... uses a famous case of international intrigue and murder to ... while treating patients with radiation poisoning. The study ... Litvinenko, the Russian dissident and former KGB operative who died ...
... delivered directly to a particularly stubborn type of breast ... of recurrence and helps increase the effectiveness of some ... MD Anderson Cancer Center reported in the Sept. 13 ... and mouse studies, scientists found the gene mutation BikDD ...
Cached Biology News:'Clumps' of opportunities for cutting edge science 2Polonium poisoning case sheds light on infection control practices 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 3
... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
... Adhesion Molecule The L1CAM ... involved in three distinct conditions: 1) HSAS ... MASA (mental retardation, aphasia, shuffling gait, adductus ... Immunogen: Homogenous suspension of ...
...
Biology Products: